688076 ST诺泰
交易中 05-15 09:48:28
资讯
新帖
简况
股市必读：ST诺泰（688076）5月14日披露最新机构调研信息
证券之星 · 02:02
股市必读：ST诺泰（688076）5月14日披露最新机构调研信息
每周股票复盘：ST诺泰（688076）收4740万罚单且净利降17.80%
证券之星 · 05-10
每周股票复盘：ST诺泰（688076）收4740万罚单且净利降17.80%
ST诺泰（688076）披露2025年度持续督导报告书，5月8日股价上涨7.18%
证券之星 · 05-08
ST诺泰（688076）披露2025年度持续督导报告书，5月8日股价上涨7.18%
ST诺泰（688076）披露2025年年度报告，4月30日股价上涨1.75%
证券之星 · 04-30
ST诺泰（688076）披露2025年年度报告，4月30日股价上涨1.75%
图解ST诺泰年报：第四季度单季净利润同比下降307.09%
证券之星 · 04-30
图解ST诺泰年报：第四季度单季净利润同比下降307.09%
每周股票复盘：ST诺泰（688076）预计一季度净利1.2亿至1.4亿
证券之星 · 04-12
每周股票复盘：ST诺泰（688076）预计一季度净利1.2亿至1.4亿
ST诺泰(688076.SH)：一季度净利润为1.20亿元—1.40亿元，同比预减8.27%—21.37%
中金财经 · 04-07
ST诺泰(688076.SH)：一季度净利润为1.20亿元—1.40亿元，同比预减8.27%—21.37%
股市必读：ST诺泰（688076）今年截至3月23日累计跌幅已超20%
证券之星 · 03-24
股市必读：ST诺泰（688076）今年截至3月23日累计跌幅已超20%
每周股票复盘：ST诺泰（688076）2025年净利降19.14%
证券之星 · 03-01
每周股票复盘：ST诺泰（688076）2025年净利降19.14%
ST诺泰发布2025年度业绩快报，盈利3.27亿元
证券之星 · 02-27
ST诺泰发布2025年度业绩快报，盈利3.27亿元
每周股票复盘：ST诺泰（688076）子公司通过药品GMP检查
证券之星 · 02-08
每周股票复盘：ST诺泰（688076）子公司通过药品GMP检查
ST诺泰最新公告：全资子公司杭州澳赛诺奥格特韦钠原料药通过GMP符合性检查
证券之星 · 02-03
ST诺泰最新公告：全资子公司杭州澳赛诺奥格特韦钠原料药通过GMP符合性检查
ST诺泰（688076）披露2026年第一次临时股东会决议公告，2月3日股价下跌1.56%
证券之星 · 02-03
ST诺泰（688076）披露2026年第一次临时股东会决议公告，2月3日股价下跌1.56%
每周股票复盘：ST诺泰（688076）预计2025年营收19亿至20亿元
证券之星 · 02-01
每周股票复盘：ST诺泰（688076）预计2025年营收19亿至20亿元
ST诺泰：预计2025年全年归属净利润盈利3.1亿元至4.2亿元
证券之星 · 01-30
ST诺泰：预计2025年全年归属净利润盈利3.1亿元至4.2亿元
每周股票复盘：ST诺泰（688076）拟申请60亿授信额度
证券之星 · 01-18
每周股票复盘：ST诺泰（688076）拟申请60亿授信额度
每周股票复盘：ST诺泰（688076）收证监会处罚决定
证券之星 · 01-11
每周股票复盘：ST诺泰（688076）收证监会处罚决定
每周股票复盘：ST诺泰（688076）签10,210万美元供货合同
证券之星 · 01-02
每周股票复盘：ST诺泰（688076）签10,210万美元供货合同
ST诺泰（688076）披露日常经营重大合同进展，12月30日股价下跌0.53%
证券之星 · 2025-12-30
ST诺泰（688076）披露日常经营重大合同进展，12月30日股价下跌0.53%
ST诺泰：醋酸阿托西班注射液获药品注册证书
财中社 · 2025-12-09
ST诺泰：醋酸阿托西班注射液获药品注册证书
公司概况
公司名称：
江苏诺泰澳赛诺生物制药股份有限公司
所属行业：
医药制造业
上市日期：
2021-05-20
主营业务：
江苏诺泰澳赛诺生物制药股份有限公司的主营业务是多肽药物及小分子化药的自主研发与定制研发生产。公司的主要产品是定制类产品、技术服务、自主选择产品。
发行价格：
15.57
{"stockData":{"symbol":"688076","market":"SH","secType":"STK","nameCN":"ST诺泰","latestPrice":31.69,"timestamp":1778809708000,"preClose":31.45,"halted":0,"volume":392489,"delay":0,"changeRate":0.0076,"floatShares":316000000,"shares":316000000,"eps":0.9786,"marketStatus":"交易中","change":0.24,"latestTime":"05-15 09:48:28","open":31.3,"high":31.95,"low":31.3,"amount":12416200,"amplitude":0.0207,"askPrice":31.69,"askSize":165,"bidPrice":31.68,"bidSize":3,"shortable":0,"etf":0,"ttmEps":0.9786,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1778815800000},"marketStatusCode":2,"adr":0,"adjPreClose":31.45,"symbolType":"stock_kcb","openAndCloseTimeList":[[1778808600000,1778815800000],[1778821200000,1778828400000]],"highLimit":33.02,"lowLimit":29.88,"ibTradeSell":true,"ibTradeBuySell":false,"totalEquity":316051897,"isCdr":false,"pbRate":3.19,"roa":"--","peRate":32.382996,"roe":"4.24%","epsLYR":1.06,"committee":-0.438914,"marketValue":10016000000,"turnoverRate":0.0012,"status":0,"floatMarketCap":10016000000},"requestUrl":"/m/hq/s/688076/wiki","defaultTab":"wiki","newsList":[{"id":"2635574787","title":"股市必读：ST诺泰（688076）5月14日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2635574787","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635574787?lang=zh_cn&edition=full","pubTime":"2026-05-15 02:02","pubTimestamp":1778781738,"startTime":"0","endTime":"0","summary":"截至2026年5月14日收盘，ST诺泰报收于31.45元，下跌2.39%，换手率0.96%，成交量3.04万手，成交额9637.67万元。来自机构调研要点：司美格鲁肽、替尔泊肽、利拉鲁肽三个GLP-1原料药2025年出货量同比大幅增长。2026年Q1营收同比下降主要因流感季节性影响，抗病毒制剂产品销售下滑；部分产品受行业价格波动影响，毛利率同比下降。公司力争2026年度营业收入较上年保持稳定增长，该预算不代表盈利预测，亦不构成对股东的承诺，存在不确定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051500001603.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688076"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634411497","title":"每周股票复盘：ST诺泰（688076）收4740万罚单且净利降17.80%","url":"https://stock-news.laohu8.com/highlight/detail?id=2634411497","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634411497?lang=zh_cn&edition=full","pubTime":"2026-05-10 01:44","pubTimestamp":1778348653,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘，ST诺泰报收于32.1元，较上周的29.73元上涨7.97%。本周，ST诺泰5月8日盘中最高价报32.2元。本周关注点公司公告汇总：公司被证监会罚款4,740万元，多名高管被警告并处罚。公司公告汇总南京证券作为江苏诺泰澳赛诺生物制药股份有限公司的保荐机构，出具2025年度持续督导报告书。2025年公司营业收入同比增长19.57%，净利润同比下降17.80%，研发投入占比上升至23.37%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051000000402.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688076"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633034452","title":"ST诺泰（688076）披露2025年度持续督导报告书，5月8日股价上涨7.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633034452","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633034452?lang=zh_cn&edition=full","pubTime":"2026-05-08 22:12","pubTimestamp":1778249543,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘，ST诺泰报收于32.1元，较前一交易日上涨7.18%，最新总市值为101.45亿元。该股当日开盘30.11元，最高32.2元，最低29.95元，成交额达2.15亿元，换手率为2.16%。近日，南京证券股份有限公司作为江苏诺泰澳赛诺生物制药股份有限公司的保荐机构，发布《关于江苏诺泰澳赛诺生物制药股份有限公司2025年度持续督导报告书》。保荐机构督促公司整改，强化公司治理与内部控制。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050800043603.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688076","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631687610","title":"ST诺泰（688076）披露2025年年度报告，4月30日股价上涨1.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631687610","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631687610?lang=zh_cn&edition=full","pubTime":"2026-04-30 18:07","pubTimestamp":1777543635,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，ST诺泰报收于29.73元，较前一交易日上涨1.75%，最新总市值为93.96亿元。该股当日开盘29.59元，最高29.99元，最低29.58元，成交额达6137.48万元，换手率为0.65%。公司于2026年4月30日披露《2025年年度报告》。报告显示，2025年公司总资产6,740,348,583.14元，归属于上市公司股东的净资产2,985,566,515.25元，营业收入1,942,799,144.82元，利润总额360,489,776.54元，归属于上市公司股东的净利润332,418,681.18元，归属于上市公司股东的扣除非经常性损益的净利润366,170,169.99元，经营活动产生的现金流量净额681,242,898.86元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000058548.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688076","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631442475","title":"图解ST诺泰年报：第四季度单季净利润同比下降307.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631442475","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631442475?lang=zh_cn&edition=full","pubTime":"2026-04-30 00:55","pubTimestamp":1777481715,"startTime":"0","endTime":"0","summary":"证券之星消息，ST诺泰2025年年报显示，当年度公司主营收入19.43亿元，同比上升19.57%；归母净利润3.32亿元，同比下降17.8%；扣非净利润3.66亿元，同比下降10.21%；其中2025年第四季度，公司单季度主营收入4.16亿元，同比上升11.56%；单季度归母净利润-1.12亿元，同比下降307.09%；单季度扣非净利润-7081.72万元，同比下降233.27%；负债率55.47%，投资收益202.56万元，财务费用5781.34万元，毛利率62.64%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000002938.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688076"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626212471","title":"每周股票复盘：ST诺泰（688076）预计一季度净利1.2亿至1.4亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2626212471","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626212471?lang=zh_cn&edition=full","pubTime":"2026-04-12 01:28","pubTimestamp":1775928489,"startTime":"0","endTime":"0","summary":"截至2026年4月10日收盘，ST诺泰报收于30.7元，较上周的29.02元上涨5.79%。本周，ST诺泰4月10日盘中最高价报31.1元。本周关注点业绩披露要点：ST诺泰预计2026年一季度扣非及归属净利润均为1.2亿元至1.4亿元。公司公告汇总：ST诺泰称一季度净利润同比减少8.27%至21.37%，主因部分产品毛利率下降。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041200000270.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688076"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625374499","title":"ST诺泰(688076.SH)：一季度净利润为1.20亿元—1.40亿元，同比预减8.27%—21.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2625374499","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625374499?lang=zh_cn&edition=full","pubTime":"2026-04-07 19:37","pubTimestamp":1775561822,"startTime":"0","endTime":"0","summary":"格隆汇4月7日丨ST诺泰(688076.SH)发布一季度业绩预告，预计一季度归属于上市公司股东的净利润为1.20亿元—1.40亿元，同比预减8.27%—21.37%；预计一季度归属于上市公司股东的扣除非经常性损益的净利润为1.20亿元—1.40亿元，同比预减7.65%—20.84%，报告期内，公司部分销售产品受行业价格波动影响，毛利率水平同比下降。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260407/32128790.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688076"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621089903","title":"股市必读：ST诺泰（688076）今年截至3月23日累计跌幅已超20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621089903","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621089903?lang=zh_cn&edition=full","pubTime":"2026-03-24 03:19","pubTimestamp":1774293592,"startTime":"0","endTime":"0","summary":"截至2026年3月23日收盘，ST诺泰报收于28.61元，下跌5.58%，换手率1.29%，成交量4.07万手，成交额1.19亿元。来自交易信息汇总：该股当年累计跌幅达23.57%，前10个交易日主力资金累计净流出1.3亿元。交易信息汇总股价提醒3月23日ST诺泰收盘报28.61元，跌5.58%，当日成交407.11万元。根据收盘数据统计，该股已连续4日下跌，当年累计跌幅23.57%。该股最近90天内共有1家机构给出评级，买入评级1家。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032400004182.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688076","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616843846","title":"每周股票复盘：ST诺泰（688076）2025年净利降19.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616843846","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616843846?lang=zh_cn&edition=full","pubTime":"2026-03-01 01:50","pubTimestamp":1772301020,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，ST诺泰报收于32.46元，较上周的33.78元下跌3.91%。本周关注点业绩披露要点：ST诺泰2025年归属净利润盈利3.27亿元，同比下降19.14%。本次计提导致公司2025年度合并报表利润总额减少9,189.23万元，最终数据以年度审计结果为准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100000472.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688076","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614858290","title":"ST诺泰发布2025年度业绩快报，盈利3.27亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614858290","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614858290?lang=zh_cn&edition=full","pubTime":"2026-02-27 20:10","pubTimestamp":1772194246,"startTime":"0","endTime":"0","summary":"证券之星消息，ST诺泰近日即将发布2025年年报，根据2月27日发布的业绩快报，归属净利润盈利3.27亿元，同比减少19.14%。2025 年末公司股本较年初增加 43.80%，主要系本年度资本公积转增股本。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022700037713.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688076","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609525264","title":"每周股票复盘：ST诺泰（688076）子公司通过药品GMP检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2609525264","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609525264?lang=zh_cn&edition=full","pubTime":"2026-02-08 02:22","pubTimestamp":1770488533,"startTime":"0","endTime":"0","summary":"截至2026年2月6日收盘，ST诺泰报收于34.8元，较上周的36.19元下跌3.84%。本周，ST诺泰2月5日盘中最高价报36.0元。本周关注点公司公告汇总：全资子公司杭州澳赛诺建德工厂奥格特韦钠原料药生产线通过药品GMP符合性检查。江苏诺泰澳赛诺生物制药股份有限公司全资子公司杭州澳赛诺生物科技有限公司近日收到浙江省药品监督管理局签发的《药品GMP符合性检查告知书》，其奥格特韦钠原料药生产线通过GMP符合性检查。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020800000716.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688076","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608293824","title":"ST诺泰最新公告：全资子公司杭州澳赛诺奥格特韦钠原料药通过GMP符合性检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2608293824","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608293824?lang=zh_cn&edition=full","pubTime":"2026-02-03 18:00","pubTimestamp":1770112846,"startTime":"0","endTime":"0","summary":"ST诺泰(688076.SH)公告称，公司全资子公司杭州澳赛诺生物科技有限公司奥格特韦钠原料药正式通过GMP符合性检查，检查范围及相关车间、生产线包括原料药（奥格特韦钠）的一车间、六车间、九车间以及B原料药生产线。这表明公司具备领先的生产及质量管理体系，对公司持续开拓创新药原料药客户具有积极意义。但产品生产、销售受多种因素影响，对近期业绩和财务数据的影响存在不确定性。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020300031643.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688076"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608541821","title":"ST诺泰（688076）披露2026年第一次临时股东会决议公告，2月3日股价下跌1.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608541821","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608541821?lang=zh_cn&edition=full","pubTime":"2026-02-03 17:35","pubTimestamp":1770111327,"startTime":"0","endTime":"0","summary":"截至2026年2月3日收盘，ST诺泰报收于34.18元，较前一交易日下跌1.56%，最新总市值为108.03亿元。该股当日开盘34.72元，最高35.1元，最低33.93元，成交额达1.62亿元，换手率为1.5%。近日，ST诺泰发布《2026年第一次临时股东会决议公告》。公告显示，公司于2026年2月2日召开2026年第一次临时股东会，会议由董事会召集，董事长童梓权主持，采用现场与网络投票结合方式表决。出席会议股东共231人，代表表决权136,073,797股，占公司总表决权的43.0542%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020300029985.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688076"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608072783","title":"每周股票复盘：ST诺泰（688076）预计2025年营收19亿至20亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608072783","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608072783?lang=zh_cn&edition=full","pubTime":"2026-02-01 01:50","pubTimestamp":1769881822,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，ST诺泰报收于36.19元，较上周的37.95元下跌4.64%。本周，ST诺泰1月26日盘中最高价报38.3元。来自公司公告汇总：ST诺泰拟2026年申请不超60亿元综合授信额度。业绩披露要点ST诺泰发布业绩预告，预计2025年全年营业收入19亿元至20亿元。预计2025年全年归属净利润盈利3.1亿元至4.2亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020100000373.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688076"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607544016","title":"ST诺泰：预计2025年全年归属净利润盈利3.1亿元至4.2亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2607544016","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607544016?lang=zh_cn&edition=full","pubTime":"2026-01-30 18:02","pubTimestamp":1769767343,"startTime":"0","endTime":"0","summary":"证券之星消息，ST诺泰发布业绩预告，预计2025年全年归属净利润盈利3.1亿元至4.2亿元。ST诺泰2025年三季报显示，前三季度公司主营收入15.27亿元，同比上升21.95%；归母净利润4.45亿元，同比上升26.92%；扣非净利润4.37亿元，同比上升23.2%；其中2025年第三季度，公司单季度主营收入4.79亿元，同比上升13.82%；单季度归母净利润1.34亿元，同比上升9.27%；单季度扣非净利润1.31亿元，同比上升4.38%；负债率53.15%，投资收益156.89万元，财务费用3731.46万元，毛利率68.46%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000032218.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688076"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2604925191","title":"每周股票复盘：ST诺泰（688076）拟申请60亿授信额度","url":"https://stock-news.laohu8.com/highlight/detail?id=2604925191","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604925191?lang=zh_cn&edition=full","pubTime":"2026-01-18 04:13","pubTimestamp":1768680786,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，ST诺泰报收于38.2元，较上周的38.87元下跌1.72%。本周，ST诺泰1月13日盘中最高价报39.84元。本周关注点公司公告汇总：ST诺泰拟在2026年度申请不超过600,000万元人民币的综合授信额度。公司公告汇总江苏诺泰澳赛诺生物制药股份有限公司将于2026年2月2日召开2026年第一次临时股东会，审议《关于向银行申请综合授信额度并提供担保的议案》。该项目募集资金承诺投资额为13,156.71万元，截至2025年12月31日累计投入7,799.63万元，使用比例为59.28%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011800001260.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688076"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2602053584","title":"每周股票复盘：ST诺泰（688076）收证监会处罚决定","url":"https://stock-news.laohu8.com/highlight/detail?id=2602053584","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602053584?lang=zh_cn&edition=full","pubTime":"2026-01-11 02:25","pubTimestamp":1768069510,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，ST诺泰报收于38.87元，较上周的37.7元上涨3.1%。本周，ST诺泰1月9日盘中最高价报39.32元。ST诺泰当前最新总市值122.85亿元，在化学制药板块市值排名49/150，在两市A股市值排名1683/5182。本周关注点公司公告汇总：ST诺泰于2025年12月17日收到证监会《行政处罚决定书》及上交所纪律处分决定。公司公告汇总南京证券作为保荐机构，对诺泰生物2025年1月1日至现场检查期间的规范运作进行了现场检查。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100000568.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688076"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2600103632","title":"每周股票复盘：ST诺泰（688076）签10,210万美元供货合同","url":"https://stock-news.laohu8.com/highlight/detail?id=2600103632","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600103632?lang=zh_cn&edition=full","pubTime":"2026-01-02 02:42","pubTimestamp":1767292930,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，ST诺泰报收于38.55元，较上周的39.07元下跌1.33%。本周，ST诺泰12月23日盘中最高价报39.81元。ST诺泰当前最新总市值119.15亿元，在化学制药板块市值排名44/150，在两市A股市值排名1638/5181。本周关注点公司公告汇总：ST诺泰全资子公司签订累计金额约10,210万美元的主服务及供货合同。2025年度合同实际履行金额约2,000万美元，占公司2024年度经审计营业收入的8.83%，占定制类产品及服务收入的29.05%。合同金额为客户采购量指引，不构成最低采购承诺。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010200000644.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688076","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2595640718","title":"ST诺泰（688076）披露日常经营重大合同进展，12月30日股价下跌0.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595640718","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595640718?lang=zh_cn&edition=full","pubTime":"2025-12-30 22:18","pubTimestamp":1767104301,"startTime":"0","endTime":"0","summary":"截至2025年12月30日收盘，ST诺泰报收于37.67元，较前一交易日下跌0.53%，最新总市值为119.06亿元。该股当日开盘37.82元，最高37.86元，最低37.65元，成交额达7778.39万元，换手率为0.65%。2025年度合同实际履行金额约2,000万美元，占公司2024年度经审计营业收入的8.83%，占定制类产品及服务收入的29.05%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123000044062.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688076","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2590928343","title":"ST诺泰：醋酸阿托西班注射液获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2590928343","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590928343?lang=zh_cn&edition=full","pubTime":"2025-12-09 19:44","pubTimestamp":1765280640,"startTime":"0","endTime":"0","summary":"12月9日，ST诺泰（维权）发布公告，公司近日收到国家药品监督管理局核准签发的醋酸阿托西班注射液的《药品注册证书》，证书编号为2025S03644、2025S03645。 醋酸阿托西班注射液是一种选择性缩宫素受体拮抗剂，适用于有早产指征的妊娠妇女，用于推迟即将出现的早产。 2025年前三季度，ST诺泰实现收入15.27亿元，归母净利润4.45亿元。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/zqgd/2025-12-09/doc-inhafezz1312149.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688076","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1778809710518,"stockEarnings":[{"period":"1week","weight":0.0501},{"period":"1month","weight":0.0168},{"period":"3month","weight":-0.069},{"period":"6month","weight":-0.2181},{"period":"1year","weight":-0.1682},{"period":"ytd","weight":-0.1658}],"compareEarnings":[{"period":"1week","weight":-0.0005},{"period":"1month","weight":0.0376},{"period":"3month","weight":0.0235},{"period":"6month","weight":0.047},{"period":"1year","weight":0.2274},{"period":"ytd","weight":0.0527}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"江苏诺泰澳赛诺生物制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"15016人(较上一季度减少1.48%)","perCapita":"21047股","listingDate":"2021-05-20","address":"江苏省连云港市连云区经济技术开发区临浦路28号","registeredCapital":"31605万元","survey":" 江苏诺泰澳赛诺生物制药股份有限公司的主营业务是多肽药物及小分子化药的自主研发与定制研发生产。公司的主要产品是定制类产品、技术服务、自主选择产品。","listedPrice":15.57},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ST诺泰(688076)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供ST诺泰(688076)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"ST诺泰,688076,ST诺泰股票,ST诺泰股票老虎,ST诺泰股票老虎国际,ST诺泰行情,ST诺泰股票行情,ST诺泰股价,ST诺泰股市,ST诺泰股票价格,ST诺泰股票交易,ST诺泰股票购买,ST诺泰股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ST诺泰(688076)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供ST诺泰(688076)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}